Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
L Kraehenbuehl, CH Weng, S Eghbali…�- Nature reviews Clinical�…, 2022 - nature.com
The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the�…
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the�…
[CITATION][C] Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
L Kraehenbuehl, CH Weng, S Eghbali…�- Nature Reviews�…, 2021 - cir.nii.ac.jp
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ�…
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ�…
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.
L Kraehenbuehl, CH Weng, S Eghbali…�- Nature reviews�…, 2021 - europepmc.org
The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the�…
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the�…
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
L Kraehenbuehl, CH Weng…�- Nature reviews�…, 2022 - pubmed.ncbi.nlm.nih.gov
The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the�…
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the�…